Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 164

Sort by

Sort Order Select

Journal Articles

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

Blood blood.2025031480.

https://doi.org/10.1182/blood.2025031480

Published: 2025

Includes: Supplemental data

Journal Articles

Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy

Dhyani Shah, Markus Perl, Matthias Fante, Severin Guetter, Simon Holzinger, Luisa-Marie Becker, Misbah Tariq, Philipp Meanauer, Simon Delahais, Gloria Lutzny-Geier, Julian Scherer, Sascha Goettert, Konstantin Herfeld, Paul Heinrich, Klaus-Georg Kreitmeier, Wolfgang Herr, Janina Doerr, Dennis Harrer, Leo Hansmann, Marcel Trefny, Matthias Edinger, Daniel Wolff, Daniela Weber, Elisabeth Meedt, André Gessner, Ernst Holler, Tobias Wertheimer, Klaus Neuhaus, Tingting Zheng, Kai Ziegler-Martin, David M. Cordas Dos Santos, Sebastian Theurich, Melanie Schirmer, Jonas Schluter, Michael Schmitt, Karin Kleigrewe, Markus Feuerer, Christoph Heuser-Loy, Jeremy Baldwin, Michael Hudecek, Luca Gattinoni, Marion Subklewe, Viktoria Blumenberg, Maria-Luisa Schubert, Christoph Stein-Thoeringer, Maik Luu, Sebastian Kobold, Erik Thiele Orberg, Hendrik Poeck

Blood (2025) 146 (Supplement 1): 2343.

https://doi.org/10.1182/blood-2025-2343

Published: 2025

Journal Articles

Patterns of patient referral for CAR-T cell therapy: Increasing access and changing utilization trends at a german tertiary care hospital from 2018 to 2024

Christian Rausch, Adrian Gottschlich, Giulia Magno, Stefanie Griesshammer, Tobias Tix, Michael Von Bergwelt, Kai Rejeski, Marion Subklewe, Veit Buecklein

Blood (2025) 146 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2025-4418

Published: 2025

Journal Articles

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Tobias Tix, Mohammad Alhomoud, Jaromir Tomasik, Gloria Iacoboni, Edward Cliff, Doris Hansen, Saad Usmani, Gilles Salles, Marion Subklewe, Michael Von Bergwelt, Samuel Yamshon, Miguel-Angel Perales, Roni Shouval, David Cordas Dos Santos, Kai Rejeski

Blood (2025) 146 (Supplement 1): 8135.

https://doi.org/10.1182/blood-2025-8135

Published: 2025

Journal Articles

Human iPSC-derived bone marrow organoids for AML engraftment and immunotherapy testing

Isabel Goek, Savannah Fairley, Daniel Berger, Anne-Sophie Neumann, Martina Kalauz, Larissa Mantoan, Monika Linder, Binje Vick, Remco Megens, Irmela Jeremias, Marion Subklewe, Stephanie Frenz-Wiessner, Christoph Klein

Blood (2025) 146 (Supplement 1): 4960.

https://doi.org/10.1182/blood-2025-4960

Published: 2025

Journal Articles

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Blood (2025) 146 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2025-1949

Published: 2025

Journal Articles

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2025-1944

Published: 2025

Journal Articles

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Blood (2025) 146 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2025-3723

Published: 2025

Journal Articles

Pre-existing clonal hematopoiesis in CAR-T recipients is not associated with increased immunotoxicity and inflammatory serum signatures

Giulia Rappa, Frank Ziemann, Kieron White, Amelie Muth, Cristina Zucchinetti, Maja Rothenberg-Thurley, Tobias Tix, Agnese Petrera, Bianka Ksienzyk, Charlotte Bentenrieder, Fabian Müller, Veit Buecklein, Kai Rejeski, Marion Subklewe

Blood (2025) 146 (Supplement 1): 2366.

https://doi.org/10.1182/blood-2025-2366

Published: 2025

Journal Articles

Allogeneic CAR-T therapy AVC-201 in AML positive for CD123

Blood (2025) 146 (Supplement 1): 3426.

https://doi.org/10.1182/blood-2025-3426

Published: 2025

Journal Articles

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Pierre Bories, Mojca Jongen-Lavrencic, Laimonas Griškevičius, Thomas Pabst, David de Leeuw, Gerwin A. Huls, Nicolas Boissel, Arnaud Pigneux, Steffen Boettcher, Mariola Dymkowska, Christiane Andrieu, Elena Fernandez, Paul Baverel, Vaia Stavropoulou, Michael Sanderson, Vladimir Kirkin, Philippe Legenne, Marion Subklewe

Blood (2025) 146 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2025-3419

Published: 2025

Journal Articles

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 5497.

https://doi.org/10.1182/blood-2025-5497

Published: 2025

Journal Articles

Pre-treatment vaccine seroprotection is markedly lower in BCMA-CAR vs CD19-CAR recipients with limited post-therapy modulation

Giulia Magno, Elif Apak, Savanna Süß, Giulia Rappa, Patricia M. Späth, Sophia Stock, Alessandra Holzem, Wajma Shahbaz, Tobias Tix, Bernhard Ismann, Judith S. Hecker, Florian Bassermann, Sebastian Theurich, Michael Von Bergwelt, Kai Rejeski, Oliver T. Keppler, Marion Subklewe, Veit Buecklein

Blood (2025) 146 (Supplement 1): 6355.

https://doi.org/10.1182/blood-2025-6355

Published: 2025

Journal Articles

Beyond ECOG: Assessment of physical function enhances risk stratification prior to CAR-T cell therapy

Alessandra Holzem, Michael Ingrisch, Anna Magee, Veronika Kezzo, Tobias Tix, Sophia Stock, Giulia Magno, Wajma Shahbaz, Michaela Braxenthaler, Michael Von Bergwelt, Wolfgang Kunz, Veit Buecklein, Sebastian Theurich, Marion Subklewe, Kai Rejeski

Blood (2025) 146 (Supplement 1): 6331.

https://doi.org/10.1182/blood-2025-6331

Published: 2025

Journal Articles

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Blood (2025) 146 (Supplement 1): 2710.

https://doi.org/10.1182/blood-2025-2710

Published: 2025

Journal Articles

Neuroinflammation detected by TSPO-PET precedes dopaminergic neuronal loss in mnt following BCMA-directed CAR-T therapy: Longitudinal multimodal neuroimaging and biomarker insights

Veit Buecklein, Katharina Mueller, Florian Schoeberl, Adrian Gottschlich, Giulia Rappa, Gerulf Haenel, Tobias Tix, Steffen Tiedt, Sophia Stoecklein, Johannes Gnoerich, Nathalie Albert, Matthias Brendel, Michael Von Bergwelt, Kai Rejeski, Marion Subklewe, Louisa von Baumgarten

Blood (2025) 146 (Supplement 1): 4172.

https://doi.org/10.1182/blood-2025-4172

Published: 2025

Journal Articles

Adipose tissue-associated lipid serum signatures modulate efficacy and toxicity of CAR-T cell therapy in lymphoid malignancies

David Cordas Dos Santos, Hannah Thurisch, Jingke Tu, Daniel Heilpern-Mallory, Amar Hadzic, Martin Kirmaier, Werner Schmitz, Martin Vaeth, Sabine Oganesian, Adriano Carboniero, Ludovica Vona, Viktoria Blumenberg, Veit Buecklein, Michael Von Bergwelt, Kai Rejeski, Marion Subklewe, Sebastian Theurich

Blood (2025) 146 (Supplement 1): 5887.

https://doi.org/10.1182/blood-2025-5887

Published: 2025

Journal Articles

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

Blood (2025) 146 (11): 1300–1313.

https://doi.org/10.1182/blood.2024027877

Published: 2025

Includes: Supplemental data

Journal Articles

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Blood (2025) 146 (7): 834–846.

https://doi.org/10.1182/blood.2025028833

Published: 2025

Includes: Supplemental data

Journal Articles

Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study

Blood (2025) 146 (5): 590–600.

https://doi.org/10.1182/blood.2024027408

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party

Multi-faceted influence of immunomodulatory metabolites on CAR-T cell therapy

Patterns of patient referral for CAR-T cell therapy: Increasing access and changing utilization trends at a german tertiary care hospital from 2018 to 2024

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Human iPSC-derived bone marrow organoids for AML engraftment and immunotherapy testing

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma

Long-term cardiovascular outcomes in patients with lymphoma who had early post-CAR-T cardiovascular events: A multi-center, international study

Pre-existing clonal hematopoiesis in CAR-T recipients is not associated with increased immunotoxicity and inflammatory serum signatures

Allogeneic CAR-T therapy AVC-201 in AML positive for CD123

Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Pre-treatment vaccine seroprotection is markedly lower in BCMA-CAR vs CD19-CAR recipients with limited post-therapy modulation

Beyond ECOG: Assessment of physical function enhances risk stratification prior to CAR-T cell therapy

Safety and efficacy of brexucabtagene autoleucel in elderly patients with relapsed or refractory Mantle Cell Lymphoma: A retrospective, multicenter, international study

Neuroinflammation detected by TSPO-PET precedes dopaminergic neuronal loss in mnt following BCMA-directed CAR-T therapy: Longitudinal multimodal neuroimaging and biomarker insights

Adipose tissue-associated lipid serum signatures modulate efficacy and toxicity of CAR-T cell therapy in lymphoid malignancies

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment

T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy

Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only